Boundless Bio CEO to Present at Leerink Global Healthcare Conference
Event summary
- Boundless Bio CEO Zachary Hornby to participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026.
- Session scheduled for 11:20 a.m. ET in Miami, Florida.
- Live and archived webcast available on Boundless Bio’s Investors page.
- Boundless Bio focuses on ecDNA biology for treating oncogene amplified cancers.
- BBI-940 is a first-in-class oral degrader of Kinesin as an ecDNA-directed therapeutic.
The big picture
Boundless Bio's participation in the Leerink Global Healthcare Conference underscores its strategic focus on ecDNA biology, a niche but promising area in oncology. The company aims to address a significant unmet need in treating oncogene amplified cancers, competing with established players and emerging biotechs in the space. The presentation provides an opportunity to gauge investor interest and industry validation for its novel approach.
What we're watching
- Clinical Development
- How the presentation will highlight progress and challenges in BBI-940's clinical trials.
- Market Positioning
- Whether Boundless Bio can differentiate itself in the competitive oncology space.
- Investor Sentiment
- The impact of the conference presentation on investor confidence and stock performance.
Related topics